Fundz

BridGene Biosciences Raises $28 Million in Series B+ Financing Led by Bayland Capital to Advance BGC-515 and Expand Platform.

PRIVATEOct 16, 2025

Amount Raised

$28 Million

Round Type

Series B

San JoseBiotechnologyTherapeutics

Investors

Gtja Investment GroupProxima VenturesLapam CapitalGrains Valley Venture CapitalBayland Capital

Description

BridGene Biosciences, a leader in small molecule drug development, announced a $28 million Series B+ funding led by Bayland Capital. The funds will be used to advance BGC-515 through clinical development and support additional oncology programs. This financing will also enhance BridGene's ability to expand its strategic collaborations and validate its IMTAC™ platform. CEO Ping Cao highlighted the significance of this funding for their lead program and pipeline development.

Who to call at BridGene Biosciences, and when

A new round usually means BridGene Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day BridGene Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at BridGene Biosciences, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

BridGene Biosciences

Location

San Jose, California, United States

About

BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and drug candidates for high-value targets.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment BridGene Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for BridGene Biosciences's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

BridGene Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.